- Johnson & Johnson (JNJ, Financial) shows promising trial results, enhancing its position in cancer treatment.
- Analyst forecasts suggest a potential upside of over 10% in JNJ stock.
- GuruFocus estimates a GF Value increase of over 20% within the next year.
Johnson & Johnson (JNJ) has recently announced encouraging results from its Phase 2b trial for TAR-200, a chemotherapy delivery system targeting certain bladder cancers. The trial demonstrated impressive statistics for patients with high-risk non-muscle-invasive bladder cancer, showing 85% and 81% disease-free survival rates at six and nine months, respectively. These results underscore the potential for TAR-200 to become a viable alternative to surgical interventions.
Wall Street Analysts Forecast
The stock market is buzzing with predictions for Johnson & Johnson (JNJ, Financial), as 24 analysts have provided their one-year price targets. The average price target stands at $170.64, with the highest estimate reaching $185.00 and the lowest at $150.00. This suggests an average potential upside of 10.39% from the current stock price of $154.58. For further analysis and detailed numbers, visit the Johnson & Johnson (JNJ) Forecast page.
In evaluating Johnson & Johnson's (JNJ, Financial) market performance, the consensus from 26 brokerage firms is pivotal. They currently rate the stock at an average of 2.3, which reflects an "Outperform" status. The rating scale ranges from 1 to 5, where 1 denotes a Strong Buy, and 5 signifies a Sell recommendation.
Turning to GuruFocus metrics, the estimated GF Value for Johnson & Johnson (JNJ, Financial) in the coming year is projected at $186.30. This indicates a potential upside of 20.52% compared to the current price of $154.58. The GF Value reflects GuruFocus' fair stock value estimate, calculated through historical trading multiples, past business growth, and future performance projections. For a deeper dive into these calculations, explore the Johnson & Johnson (JNJ) Summary page.
